CN102257135B - 流感疫苗的生产 - Google Patents

流感疫苗的生产 Download PDF

Info

Publication number
CN102257135B
CN102257135B CN200980150850.7A CN200980150850A CN102257135B CN 102257135 B CN102257135 B CN 102257135B CN 200980150850 A CN200980150850 A CN 200980150850A CN 102257135 B CN102257135 B CN 102257135B
Authority
CN
China
Prior art keywords
virus
vaccine
influenza
genes
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980150850.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN102257135A (zh
Inventor
奥特弗里德·基斯特纳
法尔科-京特·法尔科纳
哈特穆特·埃利克
诺埃尔·巴雷特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Co
Nanomedicine
Original Assignee
Baxter Healthcare SA
Nanomedicine
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Nanomedicine, Baxter International Inc filed Critical Baxter Healthcare SA
Priority to CN201710352474.6A priority Critical patent/CN107365751B/zh
Publication of CN102257135A publication Critical patent/CN102257135A/zh
Application granted granted Critical
Publication of CN102257135B publication Critical patent/CN102257135B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN200980150850.7A 2008-12-16 2009-12-16 流感疫苗的生产 Active CN102257135B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710352474.6A CN107365751B (zh) 2008-12-16 2009-12-16 流感疫苗的生产

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12296108P 2008-12-16 2008-12-16
US61/122,961 2008-12-16
PCT/US2009/068321 WO2010077986A2 (en) 2008-12-16 2009-12-16 Production of viral vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710352474.6A Division CN107365751B (zh) 2008-12-16 2009-12-16 流感疫苗的生产

Publications (2)

Publication Number Publication Date
CN102257135A CN102257135A (zh) 2011-11-23
CN102257135B true CN102257135B (zh) 2017-06-09

Family

ID=41666658

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200980150850.7A Active CN102257135B (zh) 2008-12-16 2009-12-16 流感疫苗的生产
CN201710352474.6A Active CN107365751B (zh) 2008-12-16 2009-12-16 流感疫苗的生产

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710352474.6A Active CN107365751B (zh) 2008-12-16 2009-12-16 流感疫苗的生产

Country Status (10)

Country Link
US (1) US9884105B2 (enExample)
EP (1) EP2376628B1 (enExample)
JP (1) JP5686741B2 (enExample)
KR (1) KR20110113615A (enExample)
CN (2) CN102257135B (enExample)
AU (2) AU2009333208A1 (enExample)
BR (1) BRPI0923448A2 (enExample)
ES (1) ES2675771T3 (enExample)
SG (1) SG172220A1 (enExample)
WO (1) WO2010077986A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2563389B1 (en) * 2010-04-30 2015-07-08 Temasek Life Sciences Laboratory Limited Universal vaccine against h5n1 lineages
KR101250005B1 (ko) * 2010-12-31 2013-04-03 연세대학교 산학협력단 바이러스 유전자 조작을 통한 생백신 제조방법
WO2013087945A2 (en) 2012-03-02 2013-06-20 Novartis Ag Influenza virus reassortment
US9708585B2 (en) * 2012-12-03 2017-07-18 Seqirus UK Limited Influenza virus reassortment
CA2905612A1 (en) * 2013-03-13 2014-09-18 Novartis Ag Influenza virus reassortment
CN104073513B (zh) * 2013-03-25 2018-04-20 中国科学院上海巴斯德研究所 甲型流感病毒疫苗哺乳动物细胞适应株的获得方法和适应位点
JP2016521282A (ja) * 2013-05-10 2016-07-21 ノバルティス アーゲー インフルエンザワクチンにおけるナルコレプシーのリスクの回避
CN105483149A (zh) * 2015-12-25 2016-04-13 吉林农业大学 广谱型抗禽流感重组乳酸菌及其制备方法
CN105950789A (zh) * 2016-07-14 2016-09-21 广西壮族自治区兽医研究所 一种鉴定h5亚型aiv、n6亚型aiv和aiv的引物组合及其应用
KR101966346B1 (ko) * 2017-01-13 2019-04-05 전북대학교 산학협력단 시가 독소 Stx2e를 제조하는 방법 및 이를 포함하는 부종병을 예방하기 위한 백신 조성물
JP6826203B2 (ja) 2017-08-28 2021-02-03 一般財団法人阪大微生物病研究会 リアソータントインフルエンザウイルスの段階的作出方法
KR102182987B1 (ko) * 2018-06-27 2020-11-27 대한민국 재조합 인플루엔자 a 바이러스 h5n1주 및 이를 포함하는 고병원성 인플루엔자 a 바이러스 백신 조성물
CN109096377B (zh) * 2018-09-19 2021-03-23 天康生物股份有限公司 禽流感病毒血凝素抗原及表达其的bhk-21细胞株、制备方法和疫苗
CN109134624A (zh) * 2018-09-19 2019-01-04 天康生物股份有限公司 禽流感病毒血凝素抗原及其制备方法、应用和禽流感疫苗
KR102182999B1 (ko) * 2019-01-04 2020-11-25 대한민국 재조합 인플루엔자 A 바이러스 및 이를 포함하는 clade 2.3.4.4B에 속하는 H5 혈청형 인플루엔자 A 바이러스에 대한 백신 조성물
KR102182997B1 (ko) * 2019-01-04 2020-11-26 대한민국 H5N6형 재조합 인플루엔자 A 바이러스 및 이를 포함하는 clade 2.3.4.4D에 속하는 H5 혈청형 인플루엔자 A 바이러스에 대한 백신 조성물
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral
CN111647610B (zh) * 2020-06-02 2021-09-03 扬州大学 一种互换ha和ns1缺失基因包装信号的h9n2亚型禽流感病毒及其构建方法和应用
WO2021257469A1 (en) * 2020-06-15 2021-12-23 Icahn School Of Medicine At Mount Sinai Immunoassay for the detection of anti-sars-cov-2 spike protein antibody in milk samples
CN114524862B (zh) * 2021-12-16 2022-12-27 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 禽流感(h5+h7)三价dna疫苗的构建及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008021959A2 (en) * 2006-08-09 2008-02-21 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552758A (en) 1983-12-20 1985-11-12 St. Jude Children's Research Hospital Human use of avian-human reassortants as vaccines for influenza A virus
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US6001634A (en) 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US6022726A (en) 1992-02-03 2000-02-08 Palese; Peter Genetically engineered attenuated viruses
US7344722B1 (en) 1993-06-29 2008-03-18 The Regents Of The University Of Michigan Cold-adapted influenza virus
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6146873A (en) 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
US6254873B1 (en) 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
US5840565A (en) 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
SK288544B6 (sk) 1998-06-12 2018-03-05 Mount Sinai School Of Medicine Geneticky skonštruovaný oslabený chimérny vírus chrípky, vakcinačný prostriedok a farmaceutický prostriedok s jeho obsahom a ich použitie
DE69937999T2 (de) 1998-06-12 2009-01-29 Avir Green Hills Biotechnology Research Development Trade Ag Interferon induzierende genetisch veränderte attenuierte viren
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US6803041B2 (en) 2001-03-20 2004-10-12 Boehringer Ingelheim Vetmedica, Inc. Equine herpesvirus vaccine
CN1678345B (zh) 2002-04-26 2013-09-11 米迪缪尼有限公司 制备流感病毒的多质粒系统
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
CA2807534A1 (en) 2003-02-25 2005-02-17 Medimmune Vaccines, Inc. Methods of producing influenza vaccine compositions
EP1633312A4 (en) 2003-06-16 2012-09-26 Medimmune Llc INFLUENZA HEMAGGLUTININE AND NEURAMINIDASE VARIANTS
US7037707B2 (en) 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
CN1618956A (zh) * 2003-11-20 2005-05-25 中国科学院武汉病毒研究所 一种禽流感预防用病毒株及其动物感染模型
EP1697521B1 (en) 2003-12-23 2010-06-02 MedImmune, LLC Multi plasmid system for the production of influenza virus
HUE025727T2 (en) 2004-05-24 2016-04-28 Medimmune Llc Multi-plasmid system for producing influenza virus
WO2005116260A2 (en) 2004-05-25 2005-12-08 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
BRPI0511776B1 (pt) 2004-06-01 2016-11-29 Sinai School Medicine vírus atenuado de influenza de suínos geneticamente engenheirado, formulação imunogênica, formulação farmacêutica, uso da formulação imunogênica, uso do vírus atenuado de influenza de suínos geneticamente engenheirado, uso da formulação farmacêutica e método para produzir uma vacina, uma formulação imunogênica ou uma formulação farmacêutica
EP1796719B1 (en) 2004-10-06 2014-12-03 MedImmune, LLC Refrigerator-temperature stable influenza vaccine compositions
US7510719B2 (en) 2004-12-08 2009-03-31 Medimmune, Llc Methods of producing influenza vaccine compositions
ES2527503T3 (es) 2005-03-08 2015-01-26 Medimmune, Llc Virus influenza reordenantes
ES2402061T3 (es) 2005-10-17 2013-04-26 Medimmune, Llc Método de aumento de la replicación del virus influenza
US20080014217A1 (en) 2006-07-17 2008-01-17 Emmanuel Jules Hanon Influenza vaccine
WO2008133701A1 (en) 2006-07-21 2008-11-06 Medimmune, Llc. Methods and compositions for increasing replication capacity of an influenza virus
CN101626788A (zh) 2006-09-26 2010-01-13 魁北克益得生物医学公司 用紫外光灭活流感病毒和外来因子的装置和方法
JP2010512748A (ja) 2006-12-15 2010-04-30 シェーリング−プラウ・リミテッド インフルエンザウイルスを培養物中で複製するための方法
CA2690196A1 (en) 2007-06-18 2008-12-24 Medimmune, Llc Influenza b viruses having alterations in the hemaglutinin polypeptide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008021959A2 (en) * 2006-08-09 2008-02-21 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses;Otfried Kistner;《Vaccine》;20070604;第25卷;6028-6036 *
The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate;Taisuke Horimoto;《Vaccine》;20050721;第24卷;第3671页表1，第3675页左栏第2段 *
The polymerase complex genes contribute to the high virulence of the human H5N1 infl uenza virus isolate A/Vietnam/1203/04;Rachelle Salomon;《The Journal of Experimental Medicine》;20060320;第203卷(第3期);第691页右栏第2-4段，第692页图3，第695页左栏倒数第1段-右栏第1段 *

Also Published As

Publication number Publication date
ES2675771T3 (es) 2018-07-12
WO2010077986A3 (en) 2010-10-07
CN107365751A (zh) 2017-11-21
BRPI0923448A2 (pt) 2018-10-09
JP5686741B2 (ja) 2015-03-18
CN102257135A (zh) 2011-11-23
EP2376628A2 (en) 2011-10-19
WO2010077986A2 (en) 2010-07-08
US9884105B2 (en) 2018-02-06
US20100189745A1 (en) 2010-07-29
CN107365751B (zh) 2021-07-09
JP2012511914A (ja) 2012-05-31
KR20110113615A (ko) 2011-10-17
AU2009333208A1 (en) 2010-07-08
AU2016201038A1 (en) 2016-03-10
SG172220A1 (en) 2011-07-28
EP2376628B1 (en) 2018-05-16

Similar Documents

Publication Publication Date Title
EP2376628B1 (en) Production of influenza vaccines
US11180737B2 (en) Generation of infectious influenza viruses from virus-like particles
US8597661B2 (en) Neuraminidase-deficient live influenza vaccines
EP2493502A1 (en) Process for preparing an influenza seed virus for vaccine manufacture
JP7691461B2 (ja) インフルエンザに対する免疫原性組成物
US12350325B2 (en) Recombinant high growth rate influenza virus comprising mutations in M1, NS2, and PB2
US12569550B2 (en) Hemagglutinin modifications for improved influenza vaccine production
CN113646047B (zh) 减毒活流感疫苗组合物和用于制备其的方法
CN110573613A (zh) 流感b病毒突变体及其用途
HK1163177B (en) Production of influenza vaccines
HK1163177A (en) Production of influenza vaccines
STECH et al. A NEW APPROACH TO AN INFLUENZA LIVE VACCINE: MODIFICATION OF CLEAVAGE SITE OF THE HAEMAGGLUTININ BY REVERSE GENETICS
Garn et al. A new approach to an Influenza virus live vaccine: Modification of eleavage site of the haemagglu reverse genetics
Earnest Aerosol vaccination of chickens with baculovirus expressed virus-like particles induced immune response in chickens

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1163177

Country of ref document: HK

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160923

Address after: American Florida

Applicant after: nanomedicine

Address before: Swiss Aupu

Applicant before: Baxter Co.

Effective date of registration: 20160923

Address after: Swiss Aupu

Applicant after: Baxter Co.

Address before: Illinois State

Applicant before: Baxter International Inc.

Applicant before: BAXTER HEALTHCARE S.A.

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1163177

Country of ref document: HK